Severe Asthma Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca

Posted on
by

Severe Asthma Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca
The Key Severe Asthma Companies in the market include – Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others.

 

DelveInsight’s “Severe Asthma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Severe Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Asthma Market Forecast

 

Some of the key facts of the Severe Asthma Market Report:

  • The Severe Asthma market size was valued approximately USD 7.8 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In July 2025, Asthma severity is driven by multiple inflammatory pathways, making uniform treatment challenging. Researchers are turning to precision medicine, which identifies disease subtypes using biomarkers to customize therapies. By conducting trials that match patients with treatments tailored to their biological profiles, investigators aim to replicate strategies proven effective in cancer research. This method, called a platform trial, allows for the simultaneous evaluation of several interventions in enrolled patients.

  • In May 2025, Fresh Phase 3 WAYFINDER results, shared at ATS 2025, show that tezepelumab (Tezspire) treatment can greatly reduce or even eliminate oral corticosteroid (OCS) use in adults with OCS-dependent severe asthma. Steroid dependence remains a major concern in severe asthma, as prolonged OCS use is linked to serious side effects, including cardiovascular, bone, metabolic, gastrointestinal, psychiatric issues, and adrenal insufficiency.

  • Among the European countries, the United Kingdom had the largest market size, reaching USD 430 million in 2023.

  • In 2023, the total diagnosed prevalent cases of asthma in the 7MM were approximately 43 million in adults and around 11 million in the pediatric population. These numbers are expected to increase significantly by 2034.

  • In 2023, the total number of diagnosed prevalent cases of Severe Asthma across the 7MM reached 5.1 million, accounting for roughly 9% of all diagnosed asthma cases. These cases are projected to increase significantly by 2034.

  • In 2023, the UK had the highest number of diagnosed prevalent cases of Severe Asthma (0.4 million) among the EU4 countries and the UK, followed by France with 0.3 million cases. Conversely, Spain had the lowest number of diagnosed Severe Asthma cases within the same group.

  • As per DelveInsight analysis, in Japan, the severity-specific cases segmented as intermittent, mild, moderate, and severe cases of asthma were observed to be 4 million, 0.8 million, 1 million, and 0.8 million cases, respectively in 2023. The severity-specific cases are expected to change by 2034.

  • In 2023, the US had roughly 1.2 million cases of both Type-2 inflammation severe asthma and non-type-2 inflammation severe asthma.

  • The Severe Asthma pipeline is dynamic and includes promising candidates such as GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri/Trixeo/BGF MDI) by AstraZeneca, among others, anticipated to be launched between 2023 and 2032.

  • Key Severe Asthma Companies: Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others

  • Key Severe Asthma Therapies: Cinqair (reslizumab), Fasenra (benralizumab), PT010, Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others

  • The Severe Asthma epidemiology based on gender analyzed that females are more susceptible to suffering from asthma when compared to the male population, in the 7MM

  • The Severe Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Asthma pipeline products will significantly revolutionize the Severe Asthma market dynamics.

 

Severe Asthma Overview

Severe asthma is a chronic respiratory condition characterized by persistent and intense symptoms that are difficult to control despite high doses of standard asthma medications. Unlike mild or moderate asthma, severe asthma often requires more aggressive treatment and can significantly impact a person’s quality of life.

 

Get a Free sample for the Severe Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/severe-asthma-market

 

Severe Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Severe Asthma Epidemiology Segmentation:

The Severe Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Severe Asthma

  • Prevalent Cases of Severe Asthma by severity

  • Gender-specific Prevalence of Severe Asthma

  • Diagnosed Cases of Episodic and Chronic Severe Asthma

 

Download the report to understand which factors are driving Severe Asthma epidemiology trends @ Severe Asthma Epidemiology Forecast

 

Severe Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Asthma market or expected to get launched during the study period. The analysis covers Severe Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Severe Asthma Therapies and Key Companies

  • Cinqair (reslizumab): Teva Pharmaceutical

  • Fasenra (benralizumab): AstraZeneca

  • PT010: AstraZeneca

  • Verekitug (UPB-101): Upstream Bio Inc.

  • FB704A: Oneness Biotech Co.

  • TQC2731 injection: Chia Tai Tianqing Pharmaceutical

  • Benralizumab Prefilled Syringe: Nantes University Hospital

  • Nebulized budesonide: Hamad Medical Corporation

  • povorcitinib: Incyte Corporation

  • CM326: CSPC ZhongQi Pharmaceutical

  • CM310: CSPC ZhongQi Pharmaceutical

  • Benralizumab: AstraZeneca

  • 610: Sunshine Guojian Pharmaceutical

  • Rocatinlimab: Amgen

  • Dexpramipexole Dihydrochloride: Areteia Therapeutics

  • Amlitelimab: Sanofi

  • GSK3511294 (Depemokimab): GlaxoSmithKline

  • Mepolizumab: GlaxoSmithKline

  • Flamboyant 200/12: EMS

  • AD17002: Advagene Biopharma Co.

  • TEV-56248: Teva Branded Pharmaceutical

  • FB825: Oneness Biotech Co.

 

Discover more about therapies set to grab major Severe Asthma market share @ Severe Asthma Treatment Landscape

 

Severe Asthma Market Strengths

  • Robust pipeline for severe asthma with potential medicines targeting a variety of different and more effective pathogenic mechanisms in asthma.

 

Severe Asthma Market Opportunities

  • To evaluate new candidate pharmacological interventions for severe asthma management in pediatric patient pool for which not many therapies are approved.

 

Scope of the Severe Asthma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Severe Asthma Companies: Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others

  • Key Severe Asthma Therapies: Cinqair (reslizumab), Fasenra (benralizumab), PT010, Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others

  • Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies

  • Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Severe Asthma Unmet Needs, KOL’s views, Analyst’s views, Severe Asthma Market Access and Reimbursement

 

To know more about Severe Asthma companies working in the treatment market, visit @ Severe Asthma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Severe Asthma Market Report Introduction

2. Executive Summary for Severe Asthma

3. SWOT analysis of Severe Asthma

4. Severe Asthma Patient Share (%) Overview at a Glance

5. Severe Asthma Market Overview at a Glance

6. Severe Asthma Disease Background and Overview

7. Severe Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Asthma

9. Severe Asthma Current Treatment and Medical Practices

10. Severe Asthma Unmet Needs

11. Severe Asthma Emerging Therapies

12. Severe Asthma Market Outlook

13. Country-Wise Severe Asthma Market Analysis (2020–2034)

14. Severe Asthma Market Access and Reimbursement of Therapies

15. Severe Asthma Market Drivers

16. Severe Asthma Market Barriers

17. Severe Asthma Appendix

18. Severe Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/